Third Harmonic Bio
THRD
THRD was delisted on the 30th of July, 2025.
76 hedge funds and large institutions have $523M invested in Third Harmonic Bio in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 11 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
46% more capital invested
Capital invested by funds: $358M → $523M (+$166M)
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
7% more funds holding
Funds holding: 71 → 76 (+5)
5.23% more ownership
Funds ownership: 93.05% → 98.28% (+5.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$16.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.42M |
| 3 |
CC
Commodore Capital
New York
|
+$3.65M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$3.35M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$5.3M |
| 2 |
Millennium Management
New York
|
-$1.9M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$425K |
| 4 |
Goldman Sachs
New York
|
-$391K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$289K |
THRD Hedge Fund Activity: Q2 2024 in Review
76 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q2 2024, worth a combined $523M — up 46% from $358M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new THRD positions and 11 closed out — a net gain of 5 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $16.7M. The largest seller was JP Morgan Chase, cutting an estimated $5.3M.
- 76 institutional investors held Third Harmonic Bio (THRD) as of Q2 2024, up from 71 in Q1 2024.
- Funds reported $523M of Third Harmonic Bio stock for Q2 2024, up 46% quarter-over-quarter.
- 16 funds opened new Third Harmonic Bio positions in Q2 2024 and 11 closed out, a net change of +5 holders.
- The largest Third Harmonic Bio buyer in Q2 2024 was T. Rowe Price Investment Management, an estimated $16.7M added.
- The largest Third Harmonic Bio seller in Q2 2024 was JP Morgan Chase, an estimated $5.3M sold.
Based on aggregated 13F filings for Q2 2024.